CTA
NBIX icon

Carillon Tower Advisers’s Neurocrine Biosciences NBIX Stock Holding History

Carillon Tower Advisers’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$17.1M Hold
178,671
– – 0.1% 276
2020
Q3 		$17.2M Buy
178,671
+49,071
+38% +$5.68M 0.23% 166
2020
Q2 		$15.8M Buy
+129,600
New +$14.3M 0.12% 237

Other funds holding NBIX

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Carillon Tower Advisers's NBIX Position: Q4 2020 in Review

Carillon Tower Advisers held its Neurocrine Biosciences (NBIX) position steady in Q4 2020 at 178,671 shares worth $17.1M. The position accounts for 0.1% of the portfolio, ranked #276.

Carillon Tower Advisers first reported a position in NBIX in Q2 2020 and has held it in 3 quarters since. The position peaked at $17.2M in Q3 2020. 406 funds tracked by Wall St. Rank hold NBIX as of Q4 2020.

  • Carillon Tower Advisers held 178,671 shares of Neurocrine Biosciences worth $17.1M as of Q4 2020.
  • Carillon Tower Advisers left its Neurocrine Biosciences share count unchanged in Q4 2020.
  • Neurocrine Biosciences made up 0.1% of Carillon Tower Advisers's portfolio in Q4 2020, its #276 holding.
  • Carillon Tower Advisers first reported a position in Neurocrine Biosciences in Q2 2020 and has held it in 3 quarters since.
  • Carillon Tower Advisers's Neurocrine Biosciences position peaked at $17.2M in Q3 2020.
  • 406 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.